 | |
| Clinical data | |
|---|---|
| Trade names | Rezzayo |
| Other names | Biafungin; CD101 |
| License data |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C63H85N8O17+ |
| Molar mass | 1226.4 g/mol |
Rezafungin (trade name Rezzayo) is an antifungal drug of the echinocandin class.
Rezafungin was approved by the Food and Drug Administration in March 2023 for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.